Will a prototype mRNA vaccine for H5N1 be declared successful in its Phase 3 trial by May 31, 2026?

This market resolves to Yes if the Phase 3 clinical trial results for the mRNA vaccine targeting H5N1 indicate its success in terms of efficacy and safety, as declared by the trial researchers or sponsoring organization, by May 31, 2026. News confirming the outcome of the trial must be publicly available by this date.